ASTH Astrana Health (ASTH) Insider Trading, Ownership & Congress Trades
Services · Services-management consulting services · CIK 0001083446
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
142
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $100.0K priced
What the filings say about ASTH
Congress, 1 year
No trades
Last one: purchase, 2025-08-19
Astrana Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Astrana Health, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
142 funds bought in last quarter
more than 60% of Services
Revenue
+56.4% year over year
more than 90% of Services
Margin
0.7% net margin
below 56% of Services
Buybacks
$2.8M repurchased, FY to 2026-06-30
below 81% of Services
Short interest
6.8% of the float short (float per yahoo 2026-10-26) · 5.8 days to cover · settled 2026-09-30
more than 70% of Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ASTH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+12.5%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ASTH: institutional holders (13F)
13F holdings, latest reported quarter
6,899,990 sh
$320.2M
2,605,775 sh
$120.9M
1,946,431 sh
$90.3M
1,738,930 sh
$80.7M
1,613,843 sh
$74.9M
Congress trades in ASTH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-08-19 · disclosed 11 days later
$100,001 - $250,000
Sold 2025-08-19 · disclosed 11 days later
$100,001 - $250,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ASTH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ASTH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
DIAMOND HILL SMALL CAP FUND
$19.1M position · as of 2026-06-30
6.2%
CapForce IBD 50 ETF
$2.1M position · as of 2026-07-31
2.6%
Small Company Value Portfolio
$498.9K position · as of 2026-06-30
2.0%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.7M position · as of 2026-06-30
1.9%
Select Health Care Services Portfolio
$15.0M position · as of 2026-05-31
1.9%
Global X HealthTech ETF
$339.0K position · as of 2026-05-31
1.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 142 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ASTH financials
Revenue growth
+56.4%
XBRL, annual
Net margin
0.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.8B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ASTH
| FY Dec 2025 | $3.2B |
| FY Dec 2024 | $2.0B |
| FY Dec 2023 | $1.4B |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | $773.9M |
| Jun 2026 | $972.5M |
| Mar 2026 | $965.1M |
| Dec 2025 | $950.5M |
| Sep 2025 | $956.0M |
| Jun 2025 | $654.8M |
| Mar 2025 | $620.4M |
| Dec 2024 | $665.2M |
| Sep 2024 | $478.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+1.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ASTH
| FY Dec 2025 | +0.8% |
| FY Dec 2024 | +2.5% |
| FY Dec 2023 | +4.2% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +2.0% |
| Mar 2026 | +1.5% |
| Dec 2025 | +0.8% |
| Sep 2025 | +0.0% |
| Jun 2025 | +1.4% |
| Mar 2025 | +1.1% |
| Dec 2024 | -0.0% |
| Sep 2024 | +3.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$94.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ASTH
| FY Dec 2025 | $104.5M |
| FY Dec 2024 | $44.2M |
| FY Dec 2023 | $39.7M |
| FY Dec 2022 | $59.2M |
| FY Dec 2021 | $51.1M |
| Jun 2026 | $28.9M |
| Mar 2026 | $64.1M |
| Dec 2025 | -$6.0M |
| Sep 2025 | $7.4M |
| Jun 2025 | $89.5M |
| Mar 2025 | $13.6M |
| Dec 2024 | -$13.5M |
| Sep 2024 | $31.7M |
At each fiscal year end
Single quarter
Debt to equity
1.13x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ASTH
| FY Dec 2025 | 1.33x |
| FY Dec 2024 | 0.61x |
| FY Dec 2023 | 0.45x |
| FY Dec 2022 | 0.38x |
| FY Dec 2021 | 0.41x |
| Jun 2026 | 1.13x |
| Mar 2026 | 1.28x |
| Dec 2025 | 1.33x |
| Sep 2025 | 1.35x |
| Jun 2025 | 0.54x |
| Mar 2025 | 0.56x |
| Dec 2024 | 0.61x |
| Sep 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.12x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ASTH
| FY Dec 2025 | 0.11x |
| FY Dec 2024 | 0.12x |
| FY Dec 2023 | 0.25x |
| FY Dec 2022 | 0.40x |
| FY Dec 2021 | 0.38x |
| Jun 2026 | 0.12x |
| Mar 2026 | 0.16x |
| Dec 2025 | 0.11x |
| Sep 2025 | 0.10x |
| Jun 2025 | 0.32x |
| Mar 2025 | 0.15x |
| Dec 2024 | 0.12x |
| Sep 2024 | 0.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+5.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ASTH
| FY Dec 2025 | +3.2% |
| FY Dec 2024 | +7.5% |
| FY Dec 2023 | +10.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +5.3% |
| Mar 2026 | +4.1% |
| Dec 2025 | +3.2% |
| Sep 2025 | +2.2% |
| Jun 2025 | +4.4% |
| Mar 2025 | +6.0% |
| Dec 2024 | +7.5% |
| Sep 2024 | +9.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ASTH
| FY Dec 2025 | +1.3% |
| FY Dec 2024 | +4.4% |
| FY Dec 2023 | +6.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +2.3% |
| Mar 2026 | +1.7% |
| Dec 2025 | +1.3% |
| Sep 2025 | +0.9% |
| Jun 2025 | +2.4% |
| Mar 2025 | +3.3% |
| Dec 2024 | +4.4% |
| Sep 2024 | +5.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+4.8%
operating income after a 34.7% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ASTH
| FY Dec 2025 | +3.3% |
| FY Dec 2024 | +6.8% |
| FY Dec 2023 | +9.6% |
| FY Dec 2022 | +12.5% |
| FY Dec 2021 | +16.2% |
| Jun 2026 | +4.8% |
| Mar 2026 | +3.8% |
| Dec 2025 | +3.3% |
| Sep 2025 | n/a |
| Jun 2025 | +4.7% |
| Mar 2025 | +5.8% |
| Dec 2024 | +6.8% |
| Sep 2024 | +7.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+8.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ASTH
| FY Dec 2025 | +6.1% |
| FY Dec 2024 | +10.5% |
| FY Dec 2023 | +11.0% |
| FY Dec 2022 | +13.3% |
| FY Dec 2021 | +13.5% |
| Jun 2026 | +8.0% |
| Mar 2026 | +6.7% |
| Dec 2025 | +6.1% |
| Sep 2025 | +4.7% |
| Jun 2025 | +7.3% |
| Mar 2025 | +8.7% |
| Dec 2024 | +10.5% |
| Sep 2024 | +9.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
44.86x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ASTH
| FY Dec 2025 | 52.79x |
| FY Dec 2024 | 35.03x |
| FY Dec 2023 | 29.69x |
| FY Dec 2022 | 30.19x |
| FY Dec 2021 | 48.66x |
| Jun 2026 | 55.92x |
| Mar 2026 | 39.55x |
| Dec 2025 | 52.79x |
| Sep 2025 | 141.75x |
| Jun 2025 | 47.85x |
| Mar 2025 | 42.48x |
| Dec 2024 | 35.03x |
| Sep 2024 | 44.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.6B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ASTH
| FY Dec 2025 | $2.0B |
| FY Dec 2024 | $1.9B |
| FY Dec 2023 | $2.2B |
| FY Dec 2022 | $1.6B |
| FY Dec 2021 | $4.0B |
| Jun 2026 | $3.1B |
| Mar 2026 | $1.9B |
| Dec 2025 | $2.0B |
| Sep 2025 | $2.2B |
| Jun 2025 | $1.5B |
| Mar 2025 | $1.9B |
| Dec 2024 | $1.9B |
| Sep 2024 | $3.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield ASTH
| FY Dec 2025 | +7.5% |
| FY Dec 2024 | +2.5% |
| FY Dec 2023 | +1.8% |
| FY Dec 2022 | +3.5% |
| FY Dec 2021 | +1.3% |
| Jun 2026 | +3.6% |
| Mar 2026 | +11.4% |
| Dec 2025 | +7.5% |
| Sep 2025 | +6.1% |
| Jun 2025 | +8.7% |
| Mar 2025 | +3.0% |
| Dec 2024 | +2.5% |
| Sep 2024 | +2.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.75x
P/E over trailing EPS growth of 60%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ASTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.94x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.98x |
| Jun 2026 | 0.94x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 1.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2025-01 | 2024-12 | 2023-12 | |
|---|---|---|---|---|
| Revenue | $3.2B | n/a | $2.0B | $1.4B |
| Operating income | $78.5M | n/a | $89.3M | $84.6M |
| Net income | $24.0M | n/a | $50.0M | $58.0M |
| EPS (diluted) | 0.46 | n/a | 0.90 | 1.29 |
| Operating cash flow | $114.6M | n/a | $52.2M | $68.2M |
| Cash | $429.5M | n/a | $288.5M | $293.8M |
| Long-term debt | $990.9M | n/a | $425.3M | $258.9M |
| Buybacks | $25.6M | $14.1M | $900.0K | $10.2M |
| Dividends paid | $7.9M | n/a | $4.0M | $62.1M |
SEC XBRL, fiscal years, as known on 2026-10-27
ASTH Stock Sonar score 5/7 axes
Find similar shapesCompareASTH ranks highest on growth (90th percentile) and institutional and government (60th), and lowest on risk and compliance (28th), among Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ASTH filings, in plain words
Have members of Congress traded ASTH?
Yes, but not in the year to 2026-10-27; the latest on record is a purchase by Judy Chu dated 2025-08-19.
Read the full summary
Members of Congress have disclosed trades in ASTH, none in the last year; the latest on record is a purchase by Judy Chu dated 2025-08-19. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
